Figure 3.
Targeting NF-κB Survival Signaling Using Bc-NFκBdODN Triggers B Cell Lymphoma Cell Death
(A and B) Bc-NFκBdODN treatment results in an increased cell death in human OCI-Ly3 and U2932 lymphoma cells. Cells were treated for 3 days using 5 μM Bc-NFκBdODN, control scrODN, or PBS before measuring cell viability using annexin V and 7AAD staining (A) or apoptosis using caspase-3 activation as determined by a Caspase-Glo 3/7 assay (B). Shown are representative results from one of two experiments in triplicates (means ± SD). (C–E) Local intratumoral injections of Bc-NFκBdODN reduce NF-κB activity and trigger cell death in human U2932 lymphoma in mice. Immunodeficient NSG mice were engrafted with 107 U2932 cells, and after tumors were established mice were injected intratumorally once daily during 3 days using 10 mg/kg Bc-NFκBdODN, Bc-scrODN, or PBS (n = 4–5 mice/group). NF-κB activity was detected using an EMSA assay in nuclear extracts isolated from single-cell suspensions isolated from whole tumors; n = 4 in each group. Means ± SEM are shown. Tumor tissues were collected and immunohistochemically stained for NF-κB/p65 (C) or activated caspase-3 (D).